BR112018072339A2 - tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados - Google Patents

tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados

Info

Publication number
BR112018072339A2
BR112018072339A2 BR112018072339-8A BR112018072339A BR112018072339A2 BR 112018072339 A2 BR112018072339 A2 BR 112018072339A2 BR 112018072339 A BR112018072339 A BR 112018072339A BR 112018072339 A2 BR112018072339 A2 BR 112018072339A2
Authority
BR
Brazil
Prior art keywords
hair loss
deuterated
treatment
loss disorders
jak inhibitors
Prior art date
Application number
BR112018072339-8A
Other languages
English (en)
Portuguese (pt)
Inventor
T. Wagner Amanda
V. Cassella James
B. Graham Philip
Braman Virginia
Uttamsingh Vinita
Von Hehn Jana
E. Hamilton Colleen
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018072339(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of BR112018072339A2 publication Critical patent/BR112018072339A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018072339-8A 2016-05-04 2017-05-04 tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados BR112018072339A2 (pt)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US62/331,827 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US62/338,869 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US62/418,774 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US62/419,237 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US62/434,404 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US62/466,358 2017-03-02
US201762492758P 2017-05-01 2017-05-01
US62/492,758 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
BR112018072339A2 true BR112018072339A2 (pt) 2019-02-19

Family

ID=60203616

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072339-8A BR112018072339A2 (pt) 2016-05-04 2017-05-04 tratamento de distúrbios de perda de cabelo com inibidores de jak deuterados

Country Status (21)

Country Link
US (3) US10561659B2 (cg-RX-API-DMAC7.html)
EP (2) EP4424367A3 (cg-RX-API-DMAC7.html)
JP (3) JP7145080B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190003711A (cg-RX-API-DMAC7.html)
CN (3) CN122440641A (cg-RX-API-DMAC7.html)
AU (3) AU2017261286B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072339A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022519A1 (cg-RX-API-DMAC7.html)
DK (1) DK3452039T3 (cg-RX-API-DMAC7.html)
ES (1) ES2988629T3 (cg-RX-API-DMAC7.html)
FI (1) FI3452039T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241345T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068643T2 (cg-RX-API-DMAC7.html)
LT (1) LT3452039T (cg-RX-API-DMAC7.html)
MX (6) MX388054B (cg-RX-API-DMAC7.html)
PL (1) PL3452039T3 (cg-RX-API-DMAC7.html)
PT (1) PT3452039T (cg-RX-API-DMAC7.html)
RS (1) RS66006B1 (cg-RX-API-DMAC7.html)
SI (1) SI3452039T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400389T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017192905A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561659B2 (en) * 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
EP3921318A1 (en) * 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) * 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
US12643902B2 (en) 2020-08-12 2026-06-02 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched substituted pyrrolo[2,3-d]pyrimidines
US20220213105A1 (en) 2020-08-12 2022-07-07 Concert Pharmaceuticals, Inc. Process for preparing enantiomerically enriched jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
US20230390292A1 (en) * 2020-10-28 2023-12-07 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
WO2023215520A1 (en) 2022-05-04 2023-11-09 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
WO2026020112A1 (en) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Oral formulations of deuruxolitinib
US20260027120A1 (en) * 2024-07-25 2026-01-29 Sun Pharmaceutical Industries, Inc. Methods of treatment of jak inhibition responsive conditions with deuterated jak inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
PT2635299T (pt) * 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
KR102242077B1 (ko) * 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
US10561659B2 (en) 2016-05-04 2020-02-18 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated JAK inhibitors
WO2023018904A1 (en) * 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders

Also Published As

Publication number Publication date
EP4424367A3 (en) 2024-11-13
JP2019516684A (ja) 2019-06-20
MX388054B (es) 2025-03-19
JP7586868B2 (ja) 2024-11-19
EP3452039A4 (en) 2019-12-25
AU2017261286B2 (en) 2023-03-23
SI3452039T1 (sl) 2024-12-31
JP2025026895A (ja) 2025-02-26
MX2023002325A (es) 2023-03-22
EP4424367A2 (en) 2024-09-04
AU2017261286A1 (en) 2018-11-22
AU2023201112B2 (en) 2025-05-08
JP7145080B2 (ja) 2022-09-30
US20200222408A1 (en) 2020-07-16
CN122440641A (zh) 2026-07-24
KR20190003711A (ko) 2019-01-09
US10561659B2 (en) 2020-02-18
US20240423986A1 (en) 2024-12-26
ES2988629T3 (es) 2024-11-21
HUE068643T2 (hu) 2025-01-28
KR102810262B1 (ko) 2025-05-19
PL3452039T3 (pl) 2024-11-18
EP3452039B1 (en) 2024-07-03
CA3022519A1 (en) 2017-11-09
LT3452039T (lt) 2024-10-25
MX2023002323A (es) 2023-03-22
FI3452039T3 (fi) 2024-10-02
JP2022171838A (ja) 2022-11-11
DK3452039T3 (da) 2024-10-07
MX2021014175A (es) 2022-01-04
AU2025213576A1 (en) 2025-08-21
MX2018013347A (es) 2019-09-02
MX2023002321A (es) 2023-03-22
HRP20241345T1 (hr) 2024-12-20
AU2023201112A1 (en) 2023-03-30
PT3452039T (pt) 2024-10-07
KR20250070139A (ko) 2025-05-20
KR20230086814A (ko) 2023-06-15
MX2023002324A (es) 2023-03-22
CN109069493A (zh) 2018-12-21
WO2017192905A1 (en) 2017-11-09
CN121868312A (zh) 2026-04-17
SMT202400389T1 (it) 2024-11-15
US20190160068A1 (en) 2019-05-30
US12076323B2 (en) 2024-09-03
EP3452039A1 (en) 2019-03-13
RS66006B1 (sr) 2024-10-31

Similar Documents

Publication Publication Date Title
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
BR112023016299A2 (pt) Composições e métodos para inibir kras
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
EA202190630A1 (ru) Способы комбинированной терапии
EA202091708A1 (ru) Ингибиторы днк-пк
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112023004497A2 (pt) Composto de fórmula química 1 ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica para o tratamento ou prevenção de câncer com uma mutação de egfr
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
BR112017008103A2 (pt) composto, composição farmacêutica, métodos para tratar uma doença e uma condição, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo e de um segundo agente ativo.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
CO2022000270A2 (es) Inhibidores de enzimas
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
JOP20200243A1 (ar) مركبات البلاديينوليد واستخداماتها
BR112019007543A2 (pt) inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
JOP20230090A1 (ar) نظم لعلاج الاضطرابات المتعلقة بفقدان الشعر باستخدام مثبطات jak معالجة بالديوتريوم
MX2022011203A (es) Compuestos de 9-aminometil minociclina y usos de los mismos.
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SUN PHARMACEUTICAL INDUSTRIES, INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]